¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º ='4)E6ea?  
|mRlP5  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ q 165S  
(S+/e5c)  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) JN`$Fq+  
p=E#!cn3  
1. ICAM-1 v7KBYN  
9\WtcLx  
2. interleukin 12(IL-12) U.I w/T-5  
jn(!6\n"  
3. tumor infiltrating lymphocyte YaC[S^p  
o 7tUv"Rs  
4. TCR/CD3 complex .s,04xW\  
srAWet   
5. hematopoietin receptor family K?! W9lUq  
dhnX\/  
6. individual idiotype(IdI) vazA@|^ 8  
<Lxp t  
7. integrin Eri007?D  
bfZt<-  
8. colony-stimulatory factor (CSF) +75"Q:I  
2YY4 XHQS  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ;]m;p,$  
D]}~`SO  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? IO 0n T  
UF-'(  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ }[UH1+`L  
~1}fL 1~5  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠeWex/ m  
Xxd D)I  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ Et (H6O 8  
S hy.:XI  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) (GL'm[V  
U>.5vK.+  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ JU5,\3Lz#  
tx9 %.)M:n  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) L xIKH G  
id : ^|  
3. immunoglobulin superfamily (IgSF) C(B"@   
j #P4&  
4. selectin ',WJ'g  
2 YWO'PL  
5. anti-idiotypic antibody (¦ÁId) uuD2O )v  
`fX\pOk~e  
6. major histocompatibility complex(MHC) L / WRVc6  
Et-|[ eL  
7. immunotolerance z2,NWmP|w  
i>CR{q  
8. biological reponse modifier(BRM) !.O[@A\.-  
is^R8a  
9. immune reponse gene (Ir gene) e@Ev']  
6 ]<yR> '  
10. reshaped antibody (or reconstituted antibody) =+T0[|gc(r  
04v ~ K  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© *& );-r`.  
^z, B}Nz  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ 9 4lt?|3=  
#>lbpw  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? lnjs{`^  
KV&6v`K/N  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ R N@)nc_  
BOM0QskLf  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? w;AbJCv2  
4Jc~I  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ [`tNa Vg  
[U^Cz{G  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? tK*y/S  
5-({z%:P  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 2Y[n  
-p7 HQ/  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ k6z]"[yu  
Oz]$zRu/0  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? X#ha*u~U  
w EI? 9  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ E1Q#@*rX>  
DXO'MZon3  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: LXrk5>9  
a;~< iB;3"  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ScVbo3{m*T  
a[}?!G-Wt|  
ÃâÒßѧ g@/}SJh/>  
M80O;0N%A  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© :h3 U^  
vAeVQ~  
1. CD8 ==%5Ci7qMy  
j*f\Z!EeZ  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) toOdL0hCe  
3tkCmB  
3. immunoglobulin fold(Ig fold) |_+l D|'  
 fWs*u[S  
4. cadherin (Ca-dependent cell adhesion moleculers) sP% b? 6  
gCVOm-*:  
5. idiotype-anti-idiotypic antibody immune network theory F1M:"-bda  
jt*B0'S a  
6. HLA class II antigen lU$0e09  
TpYh)=;k  
7. complementarity-determining region (CDR) UL%a^' hR  
H<?s [MH[  
8. perforin(or pore-forming protein ,PFP) TK~KM  
{L.uLr_?e  
9. high affinity IL-2 receptor 1O,8=,K2a  
7+X~i@#rU  
10. artificial active immunization Vu E$-)&)  
a <F2]H=J  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© inK ;n  
AA= eWg  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠPQh s^D  
%@TC- xx  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 w $`w  
-g|ji.  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ ^kz(/c/?  
M1*bT@ 6  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ 5)hfI7{d  
)1 HWD]>4  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ ?`O^;f  
E7aG&K  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? * >8EMq\^  
j4]3}t0q  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ hv\Dz*XTs0  
,j.bdlI#  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ #V#!@@c;?  
y%kZ##  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ b > k2@  
P*VZ$bUe5@  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ -%^'x&e  
1)z Xv  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© jF/S2Ty2  
n5^57[(  
1. immunoglobulin gene rearrangement b`^Q ':^A  
9 Qa_3+.B  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) 257$ !  
w&Gc#-B  
3. flow cytometry(FCM) fBv: TC%  
*kYGXT,f]  
4. carrier effect c$tX3ug6I  
5/7(>ivn  
5. positive selection of T lymphocytes in thymus > TBXT+  
$AE5n>ZD$  
6. mouse TH1(Th1) and TH2(Th2) subsets #(i pF  
nbf/WOCk  
7. perforin (pore-forming protein ,PFP) N@}h  
|g!d[ct]  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) iR88L&U>  
tpO '<b  
9. SH-2(src-homology region 2) y)CvlI  
6ST(=X_C  
10. Ab2¦Â (internal image) !jSgpIp  
}f?[m&<  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© QHf&Z*Xtl  
*pv<ZF0>  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? l!&ik9m  
Ef28  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? '@ Rk#=85Z  
6l;2kztGp  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ[3nWxFz$R  
kROIVO1|`  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ <r t$~}  
o.0tD  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠF4= =a8  
9 i/ (  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) 4R\jZ@D  
ftR& 5 !Wm  
ÃâÒßѧרҵ£º tO:JB&vO2  
OoH-E.lp  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ x;z=[eE  
WGUw`sc\  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? F=1 #qo<?  
T>rmm7F  
´«È¾²¡Ñ§×¨Òµ£º :,Y1#_\  
_O uNX.yrG  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ &s vg<UZ  
`Y4Kw  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ Q'Osw"  
N\g=9o|Q  
Ïû»¯×¨Òµ£º 0r1GGEW`s  
i l@>b  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ ,mp<<%{u  
"}*D,[C5e  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? 2WFZ6  
 7N[".V]c  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ 4i)5=H  
K xX[8  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 8e*skL  
W?.469yy  
1. Fas(CD95)/FasL eb\SpdM6  
T3{~f  
2. common chain of cytokine receptor |du%c`wl  
lTMY|{9  
3 . TCR/CD3 complex 3P2{M}WIl  
7b>_vtrt  
4. negaive selection of thymocytes znsQ/[  
,X^3.ILz  
5. artificial active immune )4=86>XJT  
B\RAX#  
6. anti-idiotypic 3&^hf^yg  
Jq &Hz$L|  
7. IgSF |gO7`F2  
lfHN_fE>Mq  
8. Integrin rwLKY .J]  
l2St)`K8  
9. chemokine @^UgdD,BS,  
$C7a #?YF,  
10. B7/CD28 Ra|P5  
):G%o  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© {k3ItGQ_  
.8|wc  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ paIjXaU1Mb  
,yGbMOV  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ 'r]6 GC8Z$  
Q&]|W Xv  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ !YA X.e  
QGuqV8 y0  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ $vu*# .w  
9?,i+\)qK@  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ 2]mV9B   
~x,_A>a  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ jlj ge=#c2  
N4+Cg t(  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© <4G y~?  
[ *Dj:A)V^  
1. B7/CD28 Wm6qy6HR  
?-)!dl%N  
2. Th1 subset X+]>pA  
Q)0KYKD+@  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© J~5V7B  
G*N[tw  
4. antibody affinity maturation t\ oud{Cv  
**h4M2'C  
5. AP-1 nv_vFK  
-NJpql{Cb  
6. single chain variable fragment£¨ScFv£© N~=I))i  
Dq<la+VlO  
7. NK cell receptor cRf F!EV  
Vq+7 /+2"  
8. Zinkernagel-Doherty phenomenon [cnu K  
rByth,|  
9. Ig fold 3FR(gr$X  
06]3+s{{  
10. CD40/CD40L X\Bl? F   
3cghg._  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© @6G)(NGD  
/.0K#J:  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ zTcz+3x  
&AJ bx  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ ,}IcQu'O  
/#Pm'i>B  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ zj r($?  
="$w8iRU  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ ~k&b  
O6 Py  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ @ 3=pFYW)  
{'4#{zmp  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ 73X*|g  
W5Z -s.o  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ gg#9I(pX  
P{)D_Bi   
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© $Xwk8<   
@FIL4sb  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© tM"vIz 05  
}BM`4/  
1.Co-stimulators (or co-stimulating molecules) \YzKEYx+  
bQ>wyA+G&E  
2.NK-kB AVjRhe   
M@es8\&S.  
3.Immunoglobulin superfamily y<6Sl6l*  
/4Wf\ Zu  
4.antigen-presenting cell (APC) P-ZvW<M  
"}_ J"%  
5.death domain P\Qvj7_  
9c]$d  
6.CCR and CXCR 0E#??gN  
/b # w.>e  
7.Lectin (or mitogen) g"n>v c7  
lB _9b_|2  
8.Clusters of differentiation, CD) 8US35t:M  
pHR`%2!"t  
9.B7 family UZt3U a&J  
6?}|@y^fb  
10.Cytotoxic T lymphocyte, CTL) ^e^-1s  S  
\ &|xMw[  
11.IL-15 and IL-15 receptor (IL-15R) !jl^__ .DR  
e;=R8i  
12.MHC restriction pWzYC@_W  
D A=LR  
13.Affinity-chromatography 8Q/cJ+&  
%62|dhl6  
14.Cyctosprin A, CsA d KPXs-5  
U !+O+(  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) Z]LP18m9kl  
uq6>K/~D  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© sifj mNP  
(~\HizSl  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 9r\p4_V  
85"Szc-#  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ |LIcq0Z  
@QJPcF"  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ pPsTgGai  
_Hq)@A I   
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 0 Q>  
8}oe))b  
ÃâÒßѧרҵ£º Yc[vH=gV}  
(Ms #)E  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ #m7evb5eg*  
l}S96B  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ J'#o6Ud  
\SmYxdU'>  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ vEt=en Q  
KdlUa^}D  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) 0^P9)<k'  
, Z1 &MuV  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) 4. %/u@rAi  
=;8q `  
1. ADCC(antibody dependent cell-mediated cytotoxicity) l0!`>Xx[b  
4}Os>M{k  
2. »·æß¾úËØ(cyclosporin) `sdbo](76  
7m(9|Y:Q.  
3. KIR(killer cell inhibitory receptor) k~Y_%#_  
jfR!M07|  
4. HLDA(human leucocyte differentiation antigen) sBN4:8  
<UwA5X`0e.  
5. Interleukin 18(IL-18) {y!77>Q/  
:n}t7+(>U  
6. ÕûºÏËØ(integrin) AdF[>Wv  
oM}P Wf-  
7. Fas/FasL FbPoyh  
=-uk7uZM  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) Z+;670Z  
xe1 xP@e?  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) mhnK{M @56  
'6>nXp?)r  
10. Th1/Th2 J}&xS<  
<Y#EiC.  
11. »ùÒòÒßÃç(DNAÒßÃç) itIzs99j  
TL_8c][.4$  
12. chemokines and chemokine receptor mH} 1Zy  
E%C02sI  
13. ÃâÒßÄÍÊÜ /7<l`RSr  
H23-%+*J  
14. ¹²´Ì¼¤·Ö×Ó $q;dsW,8  
Z:}d\~`x$%  
15. ËÀÍö½á¹¹Óò(death domain) 2s@<k1EdPl  
kC)ye"r  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) K%A:W  
R nf$  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? M 7;P)da  
' Nv*ePz  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ\a8<DR\@O  
aJ1 <X8  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î 7Z/KXc[b  
(r?41?5K  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ R1X{=ct  
fWywegh  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå .* xaI+:  
 0XBv8fg  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ +Q3i&"QB.  
;V~[kF=t0  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) ^F `   
!giL~}j(R  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ xFt[:G`\}u  
#?Z>o16,u  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ +KV`+zic+  
;{79d8/=  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»